A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Invasive fungal diseases (IFDs) present an increasing global burden in immunocompromised and other seriously-ill populations, including those caused by pathogens which are inherently resistant or less susceptible to antifungal drugs. Early diagnosis encompassing accurate detection and identification of the causative agent, and of antifungal resistance is critical for optimum patient outcomes. Many molecular-based diagnostic approaches have good clinical utility although interpretation of results should be according to clinical context. Where an IFD is in the differential diagnosis, panfungal PCR assays allow the rapid detection/identification of fungal species directly from clinical specimens with good specificity; sensitivity is also high when hyphae are seen in the specimen including in paraffin-embedded tissue. Aspergillus PCR assays on blood fractions have good utility in the screening of high- risk haematology patients with high negative and positive predictive values of 94% and 70%, respectively when two positive PCR results are obtained. The standardisation, and commercialisation of Aspergillus PCR assays has now enabled direct comparison of results between laboratories with commercial assays also offering the simultaneous detection of common azole resistance mutations. Candida PCR assays are not as well standardised with the only FDA-approved commercial system (T2Candida) detecting only the five most common species; whilst the T2Candida outperforms blood culture in patients with candidaemia, its role in routine Candida diagnostics is not well defined. There is growing use of Mucorales-specific PCR assays to detect selected genera in blood fractions. Quantitative real-time Pneumocystis jirovecii PCRs have replaced microscopy and immunofluorescent stains in many diagnostic laboratories although distinguishing infection may be problematic in non HIV-infected patients. For species identification of isolates, DNA barcoding with dual loci (ITS and TEF1α) offer optimal accuracy whilst next generation sequencing technologies offer highly discriminatory analysis of genetic diversity including for outbreak investigation, and for drug resistance characterisation. Advances in molecular technologies will further enhance routine fungal diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics
White, T. J., Bruns, T., Lee, S., & Taylor, J. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50042-1 · Cited by 36,648
BLAST+: architecture and applications
Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., & Madden, T. L. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-421 · Cited by 22,074
Biological identifications through DNA barcodes
Hebert, P. D. N., Cywinska, A., Ball, S. L., & deWaard, J. R. (2003) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.2002.2218 · Cited by 13,376
Reagent and laboratory contamination can critically impact sequence-based microbiome analyses
Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner, P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014) · BMC Biology · doi:10.1186/s12915-014-0087-z · Cited by 3,463
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 1×
“Additionally, WGS identified a specific mutation in the ERG11 gene associated with azole resistance (Lockhart et al., 2017).”
BackgroundChiu, C. Y., & Miller, S. A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0113-7 · Cited by 1,620
Blauwkamp, T. A., Thair, S., Rosen, M. J., Blair, L., Lindner, M. S., Vilfan, I. D., Kawli, T., Christians, F. C., Venkatasubrahmanyam, S., Wall, G. D., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0349-6 · Cited by 962
Clancy, C. J., & Nguyen, M. H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit006 · Cited by 688
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Sherry, L., Ramage, G., Kean, R., Borman, A., Johnson, E. M., Richardson, M. D., & Rautemaa-Richardson, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161320 · Cited by 420
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · cited 1×
“Of the total number of ∼20 known mutations linked to resistance, only a few mutations account for 65–80% of observed echinocandin resistance (Perlin, 2015).”
BackgroundMorschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355
Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis
Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354
van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Denning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 1×
“The exception may be in C. glabrata where azole resistance is associated with mutations in the transcription factor pdr1 (Ferrari et al., 2009), or if targeted DNA sequencing is performed for a mutation already known to confer resistance.”
BackgroundTyler, A. D., Mataseje, L., Urfano, C. J., Schmidt, L., Antonation, K. S., Mulvey, M. R., & Corbett, C. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-29334-5 · Cited by 294
Diagnosing invasive candidiasis
Clancy, C. J., & Nguyen, M. H. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01909-17 · Cited by 293
Nguyen, M. H., Wissel, M. C., Shields, R. K., Salomoni, M. A., Hao, B., Press, E. G., Shields, R. M., Cheng, S., Mitsani, D., Vadnerkar, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis200 · Cited by 290
Hasan, M. R., Rawat, A., Tang, P., Jithesh, P. V., Thomas, E., Tan, R., & Tilley, P. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03050-15 · Cited by 243
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239 · cited 1×
“Point mutations in the ERG11 gene, which encodes 14-alphademethylase, the target of the azoles, alters drug affinity and in C. albicans at least, also results in ERG11 overexpression via mutations in the transcription factor UPC2 (Flowers et al., 2012).”
BackgroundVermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Next-Generation Sequencing for Infectious Disease Diagnosis and Management
Lefterova, M. I., Suarez, C. J., Banaei, N., & Pinsky, B. A. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.07.004 · Cited by 207
Strong, M. J., Xu, G., Morici, L., Splinter Bon-Durant, S., Baddoo, M., Lin, Z., Fewell, C., Taylor, C. M., & Flemington, E. K. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004437 · Cited by 186
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Clancy, C. J., Pappas, P. G., Vazquez, J., Judson, M. A., Kontoyiannis, D. P., Thompson, G. R., Garey, K. W., Reboli, A., Greenberg, R. N., Apewokin, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1095 · Cited by 165 · cited 1×
“T2Candida was significantly more likely to be positive than cBCs (45 versus 24%, P 0.0001) (Clancy et al., 2018).”
BackgroundInfluentialChanging epidemiology of candidaemia in Australia
Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., Bak, N., Heath, C. H., Kennedy, K., Morrissey, C. O., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw422 · Cited by 163
Self-citationQuantitation of Candida CFU in Initial Positive Blood Cultures
Pfeiffer, C. D., Samsa, G. P., Schell, W. A., Reller, L. B., Perfect, J. R., & Alexander, B. D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00609-11 · Cited by 158
McMullan, R., Metwally, L., Coyle, P. V., Hedderwick, S., McCloskey, B., O'Neill, H. J., Patterson, C. C., Thompson, G., Webb, C. H., & Hay, R. J. (2008) · Clinical Infectious Diseases · doi:10.1086/528690 · Cited by 145
White, P. L., Barnes, R. A., Springer, J., Klingspor, L., Cuenca-Estrella, M., Morton, C. O., Lagrou, K., Bretagne, S., Melchers, W. J. G., Mengoli, C., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00905-15 · Cited by 140
Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance
Huang, L., Crothers, K., Atzori, C., Benfield, T., Miller, R., Rabodonirina, M., & Helweg-Larsen, J. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1010.030994 · Cited by 131
Repertoire of intensive care unit pneumonia microbiota
Bousbia, S., Papazian, L., Saux, P., Forel, J. M., Auffray, J.-P., Martin, C., Raoult, D., & La Scola, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032486 · Cited by 118
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
The Cava Trem Study Group, León, C., Ruiz-Santana, S., Saavedra, P., Castro, C., Loza, A., Zakariya, I., Úbeda, A., Parra, M., Macías, D., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1324-3 · Cited by 110 · cited 1×
“While rapid, this test does not differentiate between C. neoformans and C. gattii, and recent studies have noted poor detection of cryptococcal infection when compared with cryptococcal antigen tests (Liesman et al., 2018; Lee et al., 2019).”
ResultVallabhaneni, S., Benedict, K., Derado, G., & Mody, R. K. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw268 · Cited by 98
Diagnosis of aspergillosis by PCR: Clinical considerations and technical tips
Barnes, R. A., White, P. L., Morton, C. O., Rogers, T. R., Cruciani, M., Loeffler, J., & Donnelly, J. P. (2018) · Medical Mycology · doi:10.1093/mmy/myx091 · Cited by 68
Rapid Detection of FKS -Associated Echinocandin Resistance in Candida glabrata
Zhao, Y., Nagasaki, Y., Kordalewska, M., Press, E. G., Shields, R. K., Nguyen, M. H., Clancy, C. J., & Perlin, D. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01574-16 · Cited by 61 · cited 2×
“…assays with or without probe detection which can distinguish WT strains from those with FKS mutations (Balashov et al., 2006); (ii) microsphere-based assays using Luminex MagPix technology (Pham et al., 2014); and (iii) more sophisticated molecular beacon and melt curve assays (Zhao et al., 2016).”
MethodFortun, J., Meije, Y., Buitrago, M. J., Gago, S., Bernal-Martinez, L., Peman, J., Perez, M., Gomez-G Pedrosa, E., Madrid, N., Pintado, V., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku225 · Cited by 61 · cited 2×
“(Nguyen et al., 2012; Fortún et al., 2014; León et al., 2016; Clancy and Nguyen, 2018b).”
MethodRath, P.-M., & Steinmann, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00740 · Cited by 57
Diagnosis of invasive aspergillosis: recent developments and ongoing challenges
Arvanitis, M., & Mylonakis, E. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12448 · Cited by 56
Lee, S. H., Chen, S.-Y., Chien, J.-Y., Lee, T.-F., Chen, J.-M., & Hsueh, P.-R. (2019) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2019.04.005 · Cited by 54 · cited 2×
“The development of NGS has enabled the simultaneous sequencing of mixed microbial communities directly from a variety of clinical samples (e.g., blood, sputum, BALF, tissue, and stools) using either Illumina or Oxford Nanopore Technology (Lefterova et al., 2015; Zhou et al., 2016; Hong et al., 2018; Langelier et al.,…”
MethodSelf-citationDudiuk, C., Gamarra, S., Leonardeli, F., Jimenez-Ortigosa, C., Vitale, R. G., Afeltra, J., Perlin, D. S., & Garcia-Effron, G. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01038-14 · Cited by 50
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36
Self-citation
Cited by
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Metadata
- Authors
- Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-14
- Volume
- 10
- Pages
- 2903-2903
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2994058735
- Cited by
- 166
- References
- 47
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.